A new generation of adenosine receptor antagonists: From di- to trisubstituted aminopyrimidines
Di- and trisubstituted aminopyrimidines as adenosine receptor antagonists. New adenosine receptor ligands were designed as hybrid structures between previously synthesized substituted dicyanopyridines and aminopyrimidines, yielding two series of cyano-substituted diphenylaminopyrimidines. We were in...
Gespeichert in:
Veröffentlicht in: | Bioorganic & medicinal chemistry 2008-03, Vol.16 (6), p.2741-2752 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2752 |
---|---|
container_issue | 6 |
container_start_page | 2741 |
container_title | Bioorganic & medicinal chemistry |
container_volume | 16 |
creator | van Veldhoven, Jacobus P.D. Chang, Lisa C.W. von Frijtag Drabbe Künzel, Jacobien K. Mulder-Krieger, Thea Struensee-Link, Regina Beukers, Margot W. Brussee, Johannes IJzerman, Adriaan P. |
description | Di- and trisubstituted aminopyrimidines as adenosine receptor antagonists.
New adenosine receptor ligands were designed as hybrid structures between previously synthesized substituted dicyanopyridines and aminopyrimidines, yielding two series of cyano-substituted diphenylaminopyrimidines. We were interested in assessing the effect of this substitution pattern on both affinity and intrinsic activity, as the dicyanopyridines comprised both agonists and inverse agonists, whereas the original aminopyrimidines were exclusively inverse agonists. It was found that the new compounds were generally selective for adenosine A
1 receptors, although affinity for the adenosine A
2A receptor was also noticed for some of the compounds. In a cAMP second messenger assay the compounds behaved as inverse agonists rather than agonists. Among the more A
1 receptor-selective compounds were
5 (LUF6048),
27 (LUF6040) and
53 (LUF6056) with
K
i values of 8.1, 1.2 and 5.7
nM, respectively. |
doi_str_mv | 10.1016/j.bmc.2008.01.013 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70452361</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S096808960800014X</els_id><sourcerecordid>70452361</sourcerecordid><originalsourceid>FETCH-LOGICAL-c381t-c091bbb796c46be9f820f042dbbec7fdd235d3c753517fca62060e4abcbbaf083</originalsourceid><addsrcrecordid>eNp9kE1rFTEUhkNR2mv1B7iRbHQ315NkJjOjq1JsKxTctOuQj5OSy53kmmSU_ntT7kV3wgtn87wvh4eQ9wy2DJj8vNuaxW45wLQF1iLOyIb1su-EmNkrsoFZTh1Ms7wgb0rZAQDvZ3ZOLtjEh6kX84aoKxrxN33CiFnXkCJNnmqHMZUQkWa0eKgpUx2rfkoxlFq-0JucFupCR2uiNYeymlJDXSs6qpcQ0-E5hyW4NlDektde7wu-O91L8njz7eH6rrv_cfv9-uq-s2JitbMwM2PMOEvbS4Oznzh46LkzBu3oneNicMKOgxjY6K2WHCRgr401RnuYxCX5dNw95PRzxVLVEorF_V5HTGtRI_QDF5I1kB1Bm1MpGb06tGd1flYM1ItVtVPNqnqxqoC1iNb5cBpfzYLuX-OksQEfT4AuVu991tGG8pfjwLmEiTfu65HDpuJXwKyKDRgtutBMV-VS-M8bfwAQEZbV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70452361</pqid></control><display><type>article</type><title>A new generation of adenosine receptor antagonists: From di- to trisubstituted aminopyrimidines</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>van Veldhoven, Jacobus P.D. ; Chang, Lisa C.W. ; von Frijtag Drabbe Künzel, Jacobien K. ; Mulder-Krieger, Thea ; Struensee-Link, Regina ; Beukers, Margot W. ; Brussee, Johannes ; IJzerman, Adriaan P.</creator><creatorcontrib>van Veldhoven, Jacobus P.D. ; Chang, Lisa C.W. ; von Frijtag Drabbe Künzel, Jacobien K. ; Mulder-Krieger, Thea ; Struensee-Link, Regina ; Beukers, Margot W. ; Brussee, Johannes ; IJzerman, Adriaan P.</creatorcontrib><description>Di- and trisubstituted aminopyrimidines as adenosine receptor antagonists.
New adenosine receptor ligands were designed as hybrid structures between previously synthesized substituted dicyanopyridines and aminopyrimidines, yielding two series of cyano-substituted diphenylaminopyrimidines. We were interested in assessing the effect of this substitution pattern on both affinity and intrinsic activity, as the dicyanopyridines comprised both agonists and inverse agonists, whereas the original aminopyrimidines were exclusively inverse agonists. It was found that the new compounds were generally selective for adenosine A
1 receptors, although affinity for the adenosine A
2A receptor was also noticed for some of the compounds. In a cAMP second messenger assay the compounds behaved as inverse agonists rather than agonists. Among the more A
1 receptor-selective compounds were
5 (LUF6048),
27 (LUF6040) and
53 (LUF6056) with
K
i values of 8.1, 1.2 and 5.7
nM, respectively.</description><identifier>ISSN: 0968-0896</identifier><identifier>EISSN: 1464-3391</identifier><identifier>DOI: 10.1016/j.bmc.2008.01.013</identifier><identifier>PMID: 18258439</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adenosine ; Adenosine A 1 receptor ; Amines ; Biological and medical sciences ; Cyanopyrimidines ; Cyclic AMP ; Humans ; Inverse agonist ; Medical sciences ; Neuropharmacology ; Neurotransmitters. Neurotransmission. Receptors ; Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems ; Pharmacology. Drug treatments ; Purinergic P1 Receptor Antagonists ; Pyrimidines - chemistry ; Pyrimidines - pharmacology ; Receptor, Adenosine A1 ; Receptor, Adenosine A2A ; Structure-Activity Relationship</subject><ispartof>Bioorganic & medicinal chemistry, 2008-03, Vol.16 (6), p.2741-2752</ispartof><rights>2008 Elsevier Ltd</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c381t-c091bbb796c46be9f820f042dbbec7fdd235d3c753517fca62060e4abcbbaf083</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bmc.2008.01.013$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27911,27912,45982</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20226082$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18258439$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Veldhoven, Jacobus P.D.</creatorcontrib><creatorcontrib>Chang, Lisa C.W.</creatorcontrib><creatorcontrib>von Frijtag Drabbe Künzel, Jacobien K.</creatorcontrib><creatorcontrib>Mulder-Krieger, Thea</creatorcontrib><creatorcontrib>Struensee-Link, Regina</creatorcontrib><creatorcontrib>Beukers, Margot W.</creatorcontrib><creatorcontrib>Brussee, Johannes</creatorcontrib><creatorcontrib>IJzerman, Adriaan P.</creatorcontrib><title>A new generation of adenosine receptor antagonists: From di- to trisubstituted aminopyrimidines</title><title>Bioorganic & medicinal chemistry</title><addtitle>Bioorg Med Chem</addtitle><description>Di- and trisubstituted aminopyrimidines as adenosine receptor antagonists.
New adenosine receptor ligands were designed as hybrid structures between previously synthesized substituted dicyanopyridines and aminopyrimidines, yielding two series of cyano-substituted diphenylaminopyrimidines. We were interested in assessing the effect of this substitution pattern on both affinity and intrinsic activity, as the dicyanopyridines comprised both agonists and inverse agonists, whereas the original aminopyrimidines were exclusively inverse agonists. It was found that the new compounds were generally selective for adenosine A
1 receptors, although affinity for the adenosine A
2A receptor was also noticed for some of the compounds. In a cAMP second messenger assay the compounds behaved as inverse agonists rather than agonists. Among the more A
1 receptor-selective compounds were
5 (LUF6048),
27 (LUF6040) and
53 (LUF6056) with
K
i values of 8.1, 1.2 and 5.7
nM, respectively.</description><subject>Adenosine</subject><subject>Adenosine A 1 receptor</subject><subject>Amines</subject><subject>Biological and medical sciences</subject><subject>Cyanopyrimidines</subject><subject>Cyclic AMP</subject><subject>Humans</subject><subject>Inverse agonist</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Neurotransmitters. Neurotransmission. Receptors</subject><subject>Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems</subject><subject>Pharmacology. Drug treatments</subject><subject>Purinergic P1 Receptor Antagonists</subject><subject>Pyrimidines - chemistry</subject><subject>Pyrimidines - pharmacology</subject><subject>Receptor, Adenosine A1</subject><subject>Receptor, Adenosine A2A</subject><subject>Structure-Activity Relationship</subject><issn>0968-0896</issn><issn>1464-3391</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1rFTEUhkNR2mv1B7iRbHQ315NkJjOjq1JsKxTctOuQj5OSy53kmmSU_ntT7kV3wgtn87wvh4eQ9wy2DJj8vNuaxW45wLQF1iLOyIb1su-EmNkrsoFZTh1Ms7wgb0rZAQDvZ3ZOLtjEh6kX84aoKxrxN33CiFnXkCJNnmqHMZUQkWa0eKgpUx2rfkoxlFq-0JucFupCR2uiNYeymlJDXSs6qpcQ0-E5hyW4NlDektde7wu-O91L8njz7eH6rrv_cfv9-uq-s2JitbMwM2PMOEvbS4Oznzh46LkzBu3oneNicMKOgxjY6K2WHCRgr401RnuYxCX5dNw95PRzxVLVEorF_V5HTGtRI_QDF5I1kB1Bm1MpGb06tGd1flYM1ItVtVPNqnqxqoC1iNb5cBpfzYLuX-OksQEfT4AuVu991tGG8pfjwLmEiTfu65HDpuJXwKyKDRgtutBMV-VS-M8bfwAQEZbV</recordid><startdate>20080315</startdate><enddate>20080315</enddate><creator>van Veldhoven, Jacobus P.D.</creator><creator>Chang, Lisa C.W.</creator><creator>von Frijtag Drabbe Künzel, Jacobien K.</creator><creator>Mulder-Krieger, Thea</creator><creator>Struensee-Link, Regina</creator><creator>Beukers, Margot W.</creator><creator>Brussee, Johannes</creator><creator>IJzerman, Adriaan P.</creator><general>Elsevier Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20080315</creationdate><title>A new generation of adenosine receptor antagonists: From di- to trisubstituted aminopyrimidines</title><author>van Veldhoven, Jacobus P.D. ; Chang, Lisa C.W. ; von Frijtag Drabbe Künzel, Jacobien K. ; Mulder-Krieger, Thea ; Struensee-Link, Regina ; Beukers, Margot W. ; Brussee, Johannes ; IJzerman, Adriaan P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c381t-c091bbb796c46be9f820f042dbbec7fdd235d3c753517fca62060e4abcbbaf083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adenosine</topic><topic>Adenosine A 1 receptor</topic><topic>Amines</topic><topic>Biological and medical sciences</topic><topic>Cyanopyrimidines</topic><topic>Cyclic AMP</topic><topic>Humans</topic><topic>Inverse agonist</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Neurotransmitters. Neurotransmission. Receptors</topic><topic>Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems</topic><topic>Pharmacology. Drug treatments</topic><topic>Purinergic P1 Receptor Antagonists</topic><topic>Pyrimidines - chemistry</topic><topic>Pyrimidines - pharmacology</topic><topic>Receptor, Adenosine A1</topic><topic>Receptor, Adenosine A2A</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Veldhoven, Jacobus P.D.</creatorcontrib><creatorcontrib>Chang, Lisa C.W.</creatorcontrib><creatorcontrib>von Frijtag Drabbe Künzel, Jacobien K.</creatorcontrib><creatorcontrib>Mulder-Krieger, Thea</creatorcontrib><creatorcontrib>Struensee-Link, Regina</creatorcontrib><creatorcontrib>Beukers, Margot W.</creatorcontrib><creatorcontrib>Brussee, Johannes</creatorcontrib><creatorcontrib>IJzerman, Adriaan P.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Bioorganic & medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Veldhoven, Jacobus P.D.</au><au>Chang, Lisa C.W.</au><au>von Frijtag Drabbe Künzel, Jacobien K.</au><au>Mulder-Krieger, Thea</au><au>Struensee-Link, Regina</au><au>Beukers, Margot W.</au><au>Brussee, Johannes</au><au>IJzerman, Adriaan P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A new generation of adenosine receptor antagonists: From di- to trisubstituted aminopyrimidines</atitle><jtitle>Bioorganic & medicinal chemistry</jtitle><addtitle>Bioorg Med Chem</addtitle><date>2008-03-15</date><risdate>2008</risdate><volume>16</volume><issue>6</issue><spage>2741</spage><epage>2752</epage><pages>2741-2752</pages><issn>0968-0896</issn><eissn>1464-3391</eissn><abstract>Di- and trisubstituted aminopyrimidines as adenosine receptor antagonists.
New adenosine receptor ligands were designed as hybrid structures between previously synthesized substituted dicyanopyridines and aminopyrimidines, yielding two series of cyano-substituted diphenylaminopyrimidines. We were interested in assessing the effect of this substitution pattern on both affinity and intrinsic activity, as the dicyanopyridines comprised both agonists and inverse agonists, whereas the original aminopyrimidines were exclusively inverse agonists. It was found that the new compounds were generally selective for adenosine A
1 receptors, although affinity for the adenosine A
2A receptor was also noticed for some of the compounds. In a cAMP second messenger assay the compounds behaved as inverse agonists rather than agonists. Among the more A
1 receptor-selective compounds were
5 (LUF6048),
27 (LUF6040) and
53 (LUF6056) with
K
i values of 8.1, 1.2 and 5.7
nM, respectively.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>18258439</pmid><doi>10.1016/j.bmc.2008.01.013</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0968-0896 |
ispartof | Bioorganic & medicinal chemistry, 2008-03, Vol.16 (6), p.2741-2752 |
issn | 0968-0896 1464-3391 |
language | eng |
recordid | cdi_proquest_miscellaneous_70452361 |
source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
subjects | Adenosine Adenosine A 1 receptor Amines Biological and medical sciences Cyanopyrimidines Cyclic AMP Humans Inverse agonist Medical sciences Neuropharmacology Neurotransmitters. Neurotransmission. Receptors Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems Pharmacology. Drug treatments Purinergic P1 Receptor Antagonists Pyrimidines - chemistry Pyrimidines - pharmacology Receptor, Adenosine A1 Receptor, Adenosine A2A Structure-Activity Relationship |
title | A new generation of adenosine receptor antagonists: From di- to trisubstituted aminopyrimidines |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T22%3A27%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20new%20generation%20of%20adenosine%20receptor%20antagonists:%20From%20di-%20to%20trisubstituted%20aminopyrimidines&rft.jtitle=Bioorganic%20&%20medicinal%20chemistry&rft.au=van%20Veldhoven,%20Jacobus%20P.D.&rft.date=2008-03-15&rft.volume=16&rft.issue=6&rft.spage=2741&rft.epage=2752&rft.pages=2741-2752&rft.issn=0968-0896&rft.eissn=1464-3391&rft_id=info:doi/10.1016/j.bmc.2008.01.013&rft_dat=%3Cproquest_cross%3E70452361%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70452361&rft_id=info:pmid/18258439&rft_els_id=S096808960800014X&rfr_iscdi=true |